Schizophrenia Relapse
6
0
0
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (6)
Risk of Breakthrough Symptoms With Long-Acting Injectable Medications
Indoor Artificial Light at Night and the Relapse Risk of Schizophrenia
Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction
10-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals
Feasibility and Acceptability of a Smartphone App to Assess Early Warning Signs of Psychosis Relapse
3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals